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Ofatumumab and high-dose methylprednisolone for the
treatment of patients with relapsed or refractory chronic
lymphocytic leukemia
JE Castro1,2,3, MY Choi1,2,3, T Carvajal1, E Almahasnah1, J Chang1, DF James1 and TJ Kipps1,2
Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients
with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center. Patients received ofatumumab
(300mg then 1000mg weekly for 12 weeks) and methylprednisolone (1000 mg/m2 for 3 days of each 28-day cycle). Twenty-one
patients enrolled, including 29% with unfavorable cytogenetics (del17p or del11q). Ninety percent of patients received the full
course without dose reductions or delays. The overall response rate was 81% (17/21) with 5% complete response, 10% nodular
partial response, 67% partial response, 14% stable disease and 5% progressive disease. After a median follow-up of 31 months, the
median progression-free survival was 9.9 months and the median time to next treatment was 12.1 months. The median overall
survival has not yet been reached. The combination of high-dose methylprednisolone and ofatumumab is an effective and
tolerable treatment regimen. This regimen may be useful for patients who are unable to tolerate more aggressive therapies, or have
not responded to other treatments.
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INTRODUCTION
Although the development of chemoimmunotherapy regimens
has improved the overall survival of patients with chronic
lymphocytic leukemia (CLL), CLL is still an incurable disease, and
most patients experience relapsed disease, even after achieving
complete responses (CRs) without detectable minimal residual
disease (MRD).1 In the relapsed or refractory setting, many
patients are unable to tolerate aggressive or myelosuppressive
chemoimmunotherapy regimens owing to age, comorbidities or
pre-existing marrow suppression.2,3 Ibrutinib (Imbruvica, Pharma-
cyclics, Sunnyvale, CA, USA) was approved for the treatment of
such patients. Response rates are high, but the CR rate is low and
some patients have developed resistance owing to mutations in
the drug-binding domain.4,5
Ofatumumab (Arzerra, GlaxoSmithKline, Brentford, Middlesex,
UK) is a humanized anti-CD20 monoclonal antibody approved as a
single agent for the treatment of patients with relapsed or
refractory CLL, or in combination with chemotherapy for patients
requiring initial therapy.6 As a single agent, previous studies
reported overall response rates (ORR) of 47–58%, specifically
in patients who had disease refractory to fludarabine and
alemtuzumab, or were not candidates for alemtuzumab
therapy.7 Single-agent ofatumumab therapy infrequently achieves
CRs by objective working group criteria.8
Previously, we determined that high-dose methylprednisolone
(HDMP) and rituximab is a highly active regimen. Although single-
agent rituximab at conventional doses is associated with a low
rate of objective responses,9 rituximab in combination with
HDMP produced nearly universal responses and was safe
and well-tolerated.10,11 On the basis of this rationale, a phase II
single-center clinical trial was conducted to determine the activity
of HDMP in combination with ofatumumab in patients with
relapsed or refractory CLL.
PATIENTS AND METHODS
Patients
Patients with previously treated CLL, an indication for treatment defined by
working group guidelines, age 18 years or greater, and performance status
0–2 according to Eastern Cooperative Oncology Group (ECOG) system
were eligible for consent and enrollment.
Exclusion criteria included concurrent malignancy (excluding basal and
squamous-cell skin cancers), concurrent anti-cancer therapy, expected life
expectancy of o3 months, active bacterial or fungal systemic infections,
or HIV or Hepatitis B or C positivity by serology. Patients predicted to be
vulnerable to adverse effects of high-dose corticosteroids were also
excluded, including patients with diabetes mellitus, active peptic ulcer
disease, untreated metabolic disorders such as hypothyroidism and
Cushing’s disease, or a history of steroid-induced psychosis, pancreatitis
or diverticulitis. Patients were also excluded if known to have a
hypersensitivity to ofatumumab, or a history of anaphylaxis to rituximab
or alemtuzumab. Subjects with current active hepatic or biliary disease
(with exception of patients with Gilbert’s syndrome or asymptomatic
gallstones) were also excluded, as were subjects with uncontrolled
autoimmune hemolytic anemia or autoimmune thrombocytopenia. Finally,
patients were excluded based on the following laboratory parameters:
platelet count o50 000/μl, neutrophils o1000/μl, creatinine 42.0 times
upper normal limit, total bilirubin41.5 times upper normal limit (unless a
known history of Gilbert’s disease), alanine aminotransferase 42.5 times
upper normal limit, alkaline phosphatase 42.5 times upper normal limit.
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Study design and treatment
This was an open label, nonrandomized, single institution-based clinical
trial. Treatment with HDMP and ofatumumab was administered over
84 days in three consecutive 4-week (28 days) cycles. Patients received
HDMP sodium succinate at 1000mg/m2 body surface area (mg/m2) as a
90-min infusion for 3 consecutive days each 28-day cycle for a total of
three cycles, on days 3–5 during cycle one and on days 1–3 of cycles two
and three. Cycles 1–3 were administered without scheduled interruption
every 28 days for a total of 12 weeks of therapy. Ofatumumab 300mg was
administered on day 1 of cycle 1 followed by 12-weekly doses of 1000mg.
When ofatumumab and HDMP were administered on the same day,
ofatumumab infusions began after completion of the methylprednisolone
infusion. There was no dose reduction of ofatumumab or HDMP; in the
case of toxicity, doses were held for a maximum of 4 weeks before removal
from the study.
Subjects received allopurinol 300mg by mouth daily for 3 days before
and at least during the first cycle of treatment unless they were allergic to
allopurinol. Subjects received famotidine or equivalent before each dose of
methylprednisolone on days 1–3. Subjects also received premedication
with diphenhydramine 50mg (or equivalent antihistamine) by mouth or
by vein and acetaminophen 1000mg by mouth before each dose of
ofatumumab. On days when HDMP was not administered, subjects also
received glucocorticoids (prednisolone or equivalent) up to 50mg by vein
as premedication ~ 30min before ofatumumab infusions.
Prophylaxis against infections was mandated. All subjects received
fluconazole 100mg or alternative antifungal prophylaxis by mouth daily
while receiving treatment and for 2 months after their last cycle. All
subjects also received one tablet of trimethoprim/sulfamethoxazole DS or
alternative pneumocystis prophylaxis by mouth twice a day, three times a
week while receiving treatment and for 2 months after their last cycle.
Subjects with a history of herpes infection or zoster received acyclovir
400mg PO twice daily or alternative herpes virus prophylaxis while
receiving treatment and for 2 months after their last cycle.
Blood glucose was measured on days of HDMP administration. For blood
glucose over 201mg/dl, glycemic control was achieved by giving regular
insulin subcutaneously.
Disease status and response were assessed by history and physical and
laboratory evaluation every 4 weeks during active treatment, 2 months
after completion of treatment, at least every 3 months until 9 months after
assessment of response, and at least every 6 months thereafter until
progression or withdrawal from the study.
Efficacy
The primary end point of the study was CR based on 2008 international
working group in CLL (iwCLL) guidelines.8 Responses were assessed by the
principal investigator and confirmed by independent monitor. In
accordance with the iwCLL guidelines, CR was determined 2 months after
completion of therapy, and PR must have been maintained for42 months.
Computed tomography scans were used to confirm CRs. Secondary end
points included MRD by four-color flow cytometry, ORR, progression-free
survival (PFS) (starting from time from first ofatumumab infusion), overall
survival, safety and tolerability and correlation with biologic prognostic
factors including cytogenetics, zeta-chain-associated protein kinase 70
(ZAP-70) and immunoglobulin heavy chain (IgVH) mutations.
Safety evaluation
Severity of adverse events (AEs) was graded by investigators according
to Common Terminology Criteria for Adverse Events version 4.0 (for
nonhematologic AE) or iwCLL guidelines for hematologic AEs. Serious AEs
were monitored and reported from the time informed consent was given
until 3 years after completion of the third cycle of treatment, or until
progressive disease requiring further therapy. Subjects were removed from
the study for progressive disease identified by iwCLL criteria or serious AEs
or reactions to ofatumumab or HDMP. Blood samples were drawn at all
visits during the study period and centrally analyzed. Additional samples
were drawn at local laboratories if clinically indicated, but were not used to
determine clinical responses.
Statistical analysis
The study was powered to detect a significant improvement in CR rate
against historical controls. A sample size of 21 patients was required to
have a power of 80% (alpha of 0.05) to detect a CR rate of 20%, based on
null hypothesis CR rate of 4%. Fisher's exact test univariant analysis of
multiple variables was used to identify pretreatment patient characteristics
associated with achieving a CR or overall response to therapy. P-values
o0.05 were considered significant. Early stopping rules were based on
toxicity grade and serious AEs. The trial would have stopped if four
subjects experienced grade 4 nonhematologic toxicities deemed possibly
related to study drug, or if there were two deaths at least possibly related
to study drug.
Monitoring and study oversight
The clinical trial was approved by the University of California, San Diego
Institutional Review Board and Protocol Review and Monitoring Commit-
tee. Informed consent was obtained from all patients. Accuracy and fidelity
of all clinical, laboratory and safety data were reviewed and audited by an
independent monitor.
RESULTS
Between October 2010 and January 2012, we enrolled 21
patients with median age 63 years (range 46–75 years).
Among them 29% (6/21) were at least 70-year-old, 29% (6/21)
had a cumulative illness rating scale score 46, 29% (6/21)
had unfavorable cytogenetics (del17p or del11q) and 76%
(16/21) had CLL cells that expressed unmutated IgVH genes.
The median number of prior therapies was three. All patients
had previously received treatment with rituximab and two
patients had received prior alemtuzumab therapy. In all, 85%
(18/21) of patients had been treated with chemoimmunother-
apy regimens and 24% (5/21) had disease courses meeting
standard criteria for fludarabine resistance3 (Table 1. Patient
characteristics).
The ORR was 81% (17/21) with 5% CR (1/21), 10% nodular
partial response (PR) (2/21), 67% PR (14/21), 14% s.d. (3/21) and
5% progressive disease (1/21). The patient who achieved a CR did
not have detectable MRD in the bone marrow by four-color flow
cytometry (o0.1% of cells). After a median follow-up of
31.0 months, the median PFS was 9.9 months (range, 2–
34 months), the median treatment-free survival was 12.1 months
(range, 2–36 months) (Table 2), and the median overall survival
has not yet been reached (Figure 1).
We analyzed relevant clinical and biological variables.
Patients who achieved a response (CR or PR) had longer
survivals, as would be expected (Figure 1, middle row).
In addition, patients with adverse cytogenetics (Del 17p,
Del 11q or complex karyotype) had a lower response rate and
shorter PFS and treatment-free survival, although the sample
size was small (Figure 1, bottom row). We did not find a
significant association between ORR and PFS and any other
demographic or prognostic variables analyzed (other cyto-
genetic risk groups, age, gender, IgVH mutation, ZAP-70,
Rai stage, splenomegaly 45 cm, lymph nodes 45 cm or
fludarabine-refractory disease) (Table 3).
Safety
The treatment was well-tolerated. Ninety percent of patients
(19/21) received the full course without dose reductions or delays.
The majority of AEs were grade 1 or 2. Nineteen percent of
patients had grade 3 neutropenia and 5% had grade 3
thrombocytopenia. There were no grade 4 hematologic toxicities
and no cases of grade 3 or higher anemia. Nonhematologic
toxicities were graded according to CTCAE 4 guidelines. Recurring
grade 3 toxicities were hyperglycemia (15 patients or 71%),
nonmelanoma skin cancer or precursor skin lesions requiring
surgical intervention (4 patients or 19%). Other grade 3 toxicities
included a single episode each of pneumonia, acute coronary
syndrome, atrial fibrillation, renal calculi and hypocalcemia.
Although insomnia, anxiety, fatigue and infusion reactions were
common, they did not result in any grade 3 or 4 toxicities
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(Tables 4a and 4b). Deaths occurred during study follow-up for
four patients. One patient died of complications following
allogeneic stem cell transplant and three patients died from
progressive CLL.
DISCUSSION
In this clinical trial, we observed that the combination of HDMP
and ofatumumab is well-tolerated and highly active for the
treatment of patients with relapsed or refractory CLL. Both the
clinical effect and the safety profile compare favorably with
previously published regimens in the relapsed or refractory
setting. The AEs mainly reflected anticipated symptoms of
high-dose steroids, such as hyperglycemia, anxiety and
insomnia. Importantly, serious infections were not encountered,
although the importance and mandated use of prophylactic
antibacterial, antiviral and antifungal medications should not be
understated. Moreover, the infrequency of grade 4 myelotoxicity
makes this regimen particularly attractive for the treatment of
patients who are not able to tolerate more toxic chemotherapy-
based regimens.
The ORR of 81% was higher than that achieved with single-
agent ofatumumab in other published studies. For example, the
ORR was 50% in patients with fludarabine and alemtuzumab
refractory or ineligible patients7 and only 4.1% in the ofatumumab
arm of the RESONATE trial for patients with relapsed or refractory
CLL.12 Even though this study was not designed to make such
comparisons directly, the results presented here are encouraging.
Moreover, our study population had high-risk clinical and
biological features, including predominantly male patients or
patients with leukemic cells with high levels of ZAP-70 (62%) or
unmutated IgVH genes (76%). This study also included many
patients who would be considered heavily pretreated, with the
majority of patients having had prior chemoimmunotherapy
based treatment. Also of note, all patients in this study previously
received and progressed following rituximab therapy.
It can also be noted that HDMP and ofatumumab appear to
result in a response rate comparable to the emerging tyrosine
kinase inhibitors like Ibrutinib, with comparable tolerability and
with potential advantages including treatment cost.4,13
Potential weaknesses of this study include the modest sample
size, which was initially designed to determine the CR rate of
HDMP/ofatumumab compared with historical controls using the
HDMP-therapy backbone.10,11 The CR rate of 5% did not meet the
primary end point of this clinical study. With the majority of
patients achieving a PR, correlative laboratory studies to
determine factors associated with nonresponse were not feasible
either. Univariant analysis with a variety of biological and clinical
characteristics was statistically significant for del17p or adverse
cytogenetics, although the strength of this correlation is lessened
by the sample size as well.
The addition of HDMP allowed for the use of lower ofatumumab
doses compared with the standard dosage and schedule of
2000mg for 12 doses. In addition, the standard regimen gives the
final four doses of ofatumumab monthly, for a total treatment
duration of 6 months, whereas the duration of treatment in this
clinical trial was 3 months only. The high response rate in this
study therefore further supports the synergistic activity of anti-
CD20 antibodies with HDMP as we have previously reported using
rituximab.10,11 The decreased dose and duration of treatment with
ofatumumab in this regimen may also contribute to its feasibility
and affordability. It is also possible that the relatively brief PFS
(although still longer than previously reported with single-agent
ofatumumab) could have been improved further by additional
monthly maintenance of ofatumumab doses.
Finally, the outcome from this trial is consistent with the
previous data reported by our group showing favorable safety and
efficacy using HDMP in combination with rituximab. The CR rate
and PFS were higher with the rituximab-containing regimen;
although this study was not designed to make that comparison
directly, patient characteristics may have contributed to this result.
Regardless, HDMP appears to improve the activity of the
monoclonal antibody. We noted a higher response rate with
Table 1. Baseline patient characteristics
Characteristics No. of patients %
Median age of patients in the study
4 65 11 52
65 or younger 10 48
Sex
Male 18 86
Female 3 14
Prior treatment
42 prior regimens 11 52
2 or fewer prior regimens 10 48
Prior chemoimmunotherapy 14 67
Prior rituximab-containing regimen 21 100
Fludarabine refractory 5 24
Rai stage at screening
0 0 0
1 or 2 7 33
3 or 4 14 67
Cytogenetics/ FISH
del17p 4 19
del11q 2 10
Trisomy 12 4 19
del13q 4 19
Other abnormalities 2 10
Normal karyotype 5 24
ZAP-70
Positive 13 62
Negative 7 33
No information 1 5
IgVH
Unmutated 16 76
Mutated 5 24
Performance status (ECOG)
0 14 67
1-2 7 33
CIRS score
4 6 6 29
6 or less 15 71
Abbreviations: CRIS, cumulative illness rating scale; ECOG, Eastern Coopera-
tive Oncology Group; FISH, fluorescence in situ hybridization; IgVH,
immunoglobulin heavy chain; ZAP-70, zeta-chain-associated protein kinase 70.
Table 2. Summary of responses by iwCLL category
No. of patients Percent
Complete response 1 4.8
MRD negative 1 4.8
MRD positive 0 0
Nodular partial response 2 9.5
Partial response 14 66.7
Stable disease 3 14.3
Progressive disease 1 4.8
Abbreviations: iwCLL, international working group in chronic lymphocytic
leukemia; MRD, minimal residual disease.
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the combination than previously reported with treatment with the
antibody alone. This supports additional clinical trials of this
approach with other monoclonal antibodies, such as Gazyva
(obinutuzumab, Genentech, South San Francisco, CA, USA).14
Figure 1. PFS (a), Treatment-free survival (b) and overall survival (c) graphed for all patients (top row), according to response to therapy
(middle row) and according to cytogenetic risk group, with Del(17p), Del(11q) or complex cytogenetics considered adverse (bottom row).
Copyright: 123
Table 3. Responses by patient characteristics
Characteristics/variable OR CI 95% P-value
Demographics
Age (465) 1.1 0.1–9.9 1.0
Female 2.2 0.09–51 1.0
Baseline ECOG40 0.42 0.04–3.8 0.57
Cytogenetics
del17p 0.02 0.001–0.43 0.01
del11q 0.12 0.005–2.7 0.27
Trisomy 12 3.0 0.1–67.3 0.55
del13q 3.0 0.1–67.3 0.55
Prognostic/biologic
IgVH unmutated (498%) 0.25 0.01–5.5 0.53
ZAP-70 (420% expression) 0.56 0.05–6.7 1.0
β2-Microglobulin (42 × ULN) 0.42 0.05–3.8 0.57
Clinical
High Rai (⩾3) 0.61 0.05–7.2 1.0
LN pretreatment 45 cm 0.64 0.05–8.5 1.0
Splenomegaly pre-tx 45cm 5.1 0.2–110.3 0.28
Fludarabine refractory 0.92 0.07–11.5 1.0
Prior regimens42 0.08 0.004–1.7 0.09
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology
Group; OR, odds ratio.
Table 4a. Nonhematologic adverse events
Adverse Events Total (%) Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia 20 (95%) — 10 (48%) 10 (48%) —
Insomnia 16 (76%) 14 (67%) 2 (10%) — —
Fatigue 12 (57%) 8 (38%) 4 (19%) — —
Infusion reaction 11 (52%) 5 (24%) 6 (29%) — —
Rash 11 (52%) 9 (43%) 2 (10%) — —
Upper respiration
infection
11 (52%) 4 (19%) 7 (33%) — —
Hypokalemia 9 (43%) 8 (38%) 1 (5%) — —
Anxiety 8 (38%) 7 (33%) 1 (5%) — —
Arrhythmia 7 (33%) 5 (24%) 1 (5%) 1 (5%) —
Elevated ALT
(SGPT)
7 (33%) 6 (29%) 1 (5%) — —
Hypocalcemia 7 (33%) 5 (24%) 1 (5%) 1 (5%) —
Abdominal pain 6 (29%) 5 (24%) 1 (5%) — —
Back pain 6 (29%) 5 (24%) 1 (5%) — —
Allergic rhinitis 4 (19%) 2 (10%) 2 (10%) — —
Hyperkalemia 3 (14%) 2 (10%) 1 (5%) — —
Weakness 3 (14%) 2 (10%) 1 (5%) — —
Weight gain 3 (14%) 2 (10%) 1 (5%) — —
Cough 2 (10%) 1 (5%) 1 (5%) — —
Hyperhidrosis 2 (10%) 1 (5%) 1 (5%) — —
Pneumonia 1 (5%) — — 1 (5%) —
Influenza 1 (5%) — — 1 (5%) —
Kidney stone 1 (5%) — — 1 (5%) —
Myocardial
infarction
1 (5%) — — 1 (5%) —
Squamous cell
skin cancer
1 (5%) — — 1 (5%) —
Abbreviation: ALT, alanine aminotransferase; SGPT, serum glutamate
pyruvate transaminase.
Ofatumumab and HDMP for CLL
JE Castro et al
4
Blood Cancer Journal © 2014 Macmillan Publishers Limited
In summary, HDMP and ofatumumab is a well-tolerated
regimen despite the presence of comorbid conditions in
high-risk CLL patients. In addition, this combination is associated
with a high response rate that can be achieved within 3 months of
initiation of therapy. As both agents are clinically approved and
readily available, this regimen constitutes a valid alternative for
patients with relapsed or refractory CLL.
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